Details:
Novel PCOS drug target, is largely unknown, genomic studies suggest a strong genetic connection from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2022